Education
About Us
Working with TipRanks
Follow Us
Lyell Immunopharma (LYEL)
NASDAQ:LYEL
LYEL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.48 - $3.15
Previous CloseN/A
Volume124.06K
Average Volume (3M)918.08K
Market Cap
$142.98M
Enterprise Value-$28.27M
Total Cash (Recent Filing)$105.60M
Total Debt (Recent Filing)$58.97M
Price to Earnings (P/E)―
Beta2.38
Next Earnings
May 13, 2025EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.31
Shares Outstanding295,228,880
10 Day Avg. Volume913,139
30 Day Avg. Volume918,084
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2799.83
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.20
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-463.37
Enterprise Value/Ebitda0.14
Forecast
1Y Price Target
$1.00Price Target Upside117.39% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering2
---
Lyell Immunopharma News
PremiumCompany Announcements
Lyell Immunopharma’s LyFE Center Begins IMPT-314 Production
PremiumCompany Announcements
Lyell Immunopharma Advances CAR T-Cell Therapy Pipeline
---
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyData from a single-center Phase 1 study demonstrated 92% ORR with 77% CRs, mPFS of 50 months, and mOS not yet reached.
Financial ResourcesLyell ended 4Q24 with $383.5 million in cash, which management expects to provide an operational runway into 2027.
Strategic FocusThe acquisition of ImmPACT Biosciences focuses Lyell Immunopharma on a promising CAR-T cell therapy for B-cell lymphomas.
Bears Say
Competitive PressureThe CD19-targeted CAR-T space is crowded, and the opportunity for another entrant like Lyell is limited.
Financial PerformanceLyell reported a net loss of $0.69 per share, which was worse than the analyst's estimate of a net loss of $0.18 per share.
Strategic UncertaintyThe decision to discontinue next-gen, early-stage, solid tumor CAR-T LYL119 adds to the uncertainty surrounding Lyell's strategy.
---
Ownership Overview
17.85% Insiders
7.03% Mutual Funds
31.04% Other Institutional Investors
37.33% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LYEL FAQ
What was Lyell Immunopharma’s price range in the past 12 months?
Lyell Immunopharma lowest stock price was $0.48 and its highest was $3.15 in the past 12 months.
What is Lyell Immunopharma’s market cap?
Lyell Immunopharma’s market cap is $142.98M.
When is Lyell Immunopharma’s upcoming earnings report date?
Lyell Immunopharma’s upcoming earnings report date is May 13, 2025 which is in 38 days.
How were Lyell Immunopharma’s earnings last quarter?
Lyell Immunopharma released its earnings results on Mar 11, 2025. The company reported -$0.705 earnings per share for the quarter, missing the consensus estimate of -$0.17 by -$0.535.
Is Lyell Immunopharma overvalued?
According to Wall Street analysts Lyell Immunopharma’s price is currently Undervalued.
Does Lyell Immunopharma pay dividends?
Lyell Immunopharma does not currently pay dividends.
What is Lyell Immunopharma’s EPS estimate?
Lyell Immunopharma’s EPS estimate is -0.18.
How many shares outstanding does Lyell Immunopharma have?
Lyell Immunopharma has 295,228,880 shares outstanding.
What happened to Lyell Immunopharma’s price movement after its last earnings report?
Lyell Immunopharma reported an EPS of -$0.705 in its last earnings report, missing expectations of -$0.17. Following the earnings report the stock price went up 1.515%.
Which hedge fund is a major shareholder of Lyell Immunopharma?
Currently, no hedge funds are holding shares in LYEL
---
Lyell Immunopharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$1.00 (117.39% Upside)
$1.00 (117.39% Upside)
Blogger Sentiment
Neutral
LYEL Sentiment 50%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 155.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $443.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.0%
Last 30 Days ▲ 20.6%
Last 30 Days ▲ 20.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-75.62%
12-Months-Change
Fundamentals
Return on Equity
-66.10%
Trailing 12-Months
Asset Growth
-34.55%
Trailing 12-Months
Company Description
Lyell Immunopharma
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
---
LYEL Stock 12 Month Forecast
Average Price Target
$1.00
▲(117.39% Upside)
Technical Analysis
Bluebird Bio
―
Fate Therapeutics
―
Iovance Biotherapeutics
―
Adaptimmune Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering LYEL
1 Year
1 Year Success Rate
3/4 ratings generated profit
1 Year Average Return
+14.25%
reiterated a sell rating 8 days ago
Copying Jason Zemansky's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +14.25% per trade.
---